Medicine
Akynzeo 260 mg/0.28 mg per 20 mL injection
Akynzeo 260 mg/0.28 mg per 20 mL injection is a prescription medicine containing Fosnetupitant and Palonosetron for intravenous use, marketed by Helsinn Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store AKYNZEO for injection in carton, protected from light at 2° to 8°C (35.6…
Key facts
- Active ingredient (INN)
- Fosnetupitant and Palonosetron
- Brand
- Akynzeo
- Strength
- 260 mg/0.28 mg per 20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 20 mL
- Marketing authorisation holder
- Helsinn Therapeutics
- Manufacturer
- Helsinn Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store AKYNZEO for injection in carton, protected from light at 2° to 8°C (35.6 F to 46.4°F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 June 2020
- Identifiers
- RxCUI 1552343, 1552349, 2044429 +3DailyMed set ID 8e47618e-af46-4d82-94e8-1507c042252dNDC 69639-105, 69639-106Application NDA210493
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 20 mL in 1 vial | 69639-105-01 | Helsinn Therapeutics | 15 June 2020 |
| 1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 69639-106-01 | Helsinn Therapeutics | 1 August 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 19 April 2018 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Fosnetupitant and Palonosetron is a fixed-dose combination medicine. It is available as injection for intravenous use. MedsAcross supplies Fosnetupitant and Palonosetron for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Fosnetupitant and PalonosetronFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- AKYNZEO prescribing information (Helsinn Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Akynzeo 260 mg/0.28 mg per 20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.